LDS/Medical Tests/Neurotrophic Receptor Tyrosine Kinase 1 (NTRK1) Gene Mutation Analysis (Translocation)

Neurotrophic Receptor Tyrosine Kinase 1 (NTRK1) Gene Mutation Analysis (Translocation)

The NTRK1 gene encodes neurotrophic receptor tyrosine kinase 1, a membrane-bound receptor essential for the development, differentiation, and survival of sensory neurons. Upon binding to its ligand, nerve growth factor (NGF), NTRK1 undergoes autophosphorylation and activates downstream signaling pathways, including MAPK/ERK, PI3K/AKT, and PLCγ, which regulate neuronal growth and synaptic maintenance.

Pathogenic variants or fusions involving NTRK1 can lead to either neurodevelopmental disorders or oncogenic transformation, depending on the nature of the alteration.

  • Loss-of-function mutations result in Congenital Insensitivity to Pain with Anhidrosis (CIPA), a rare autosomal recessive disorder characterized by the inability to feel pain and temperature, recurrent injuries, and anhidrosis due to autonomic nervous system dysfunction. These mutations disrupt NTRK1 signaling and trigger sensory neuron apoptosis.
  • Gain-of-function or fusion mutations involving TPM3, TPR, or TFG genes generate constitutively active NTRK1 fusion proteins, which act as oncogenic drivers in a subset of papillary thyroid carcinomas and other solid tumors. Such gene rearrangements lead to ligand-independent activation of the MAPK pathway and uncontrolled cellular proliferation.

The NTRK1 Gene Mutation Analysis detects sequence variants and translocations within the NTRK1 locus using high-sensitivity molecular techniques. It assists in both genetic diagnosis of hereditary sensory neuropathy and oncogenic fusion detection in cancer profiling.

  • Confirms genetic diagnosis of CIPA and other hereditary sensory or autonomic neuropathies
  • Aids in the molecular characterization of papillary thyroid carcinoma and other malignancies harboring NTRK1 fusions
  • Guides targeted therapy decisions using TRK inhibitors (e.g., larotrectinib, entrectinib) in oncology settings

Positive Result: Detection of an NTRK1 pathogenic variant or fusion consistent with CIPA or NTRK1 fusion–driven malignancies.

Negative Result: No detectable NTRK1 mutation or rearrangement; however, the absence of mutation does not exclude disease, and clinical correlation is required.

Negative (no pathogenic variant or rearrangement detected)

Polymerase chain reaction (PCR) and next-generation sequencing (NGS) for detection of point mutations, small insertions/deletions, and translocations.

Whole blood EDTA.

Stability

  • Ambient: 3-5 days
  • Refrigerated: 7-14 day
  • Frozen: Unstable
NTRK2 and NTRK3 gene fusion testing, RET and BRAF mutation analysis (for thyroid malignancies), Comprehensive neuropathy gene panel.
5-10 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login